Drugs / rF1V
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00097396 | Nov 2004 → Jul 2006 | pneumonic plague | DynPort Vaccine Company LLC, A GDIT Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05506969 | Aug 2022 → Oct 2023 | pneumonic plague | Dynavax Technologies Corporation | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01122784 Comparator | Jul 2010 → May 2012 | plague | DynPort Vaccine Company LLC, A GDIT Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rF1V | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01122784 ↗ |
| Known as | Recombinant Plague Vaccine rF1V | “Recombinant Plague Vaccine rF1V” NCT01122784 ↗ |
| Modality | Vaccine | “recombinant plague vaccine rF1V” NCT00097396 ↗ |
| Route | Intramuscular | “given as an intramuscular (IM) injection” NCT00097396 ↗ |